Connect with us

Hi, what are you looking for?

POZ

Very early treatment of newborns with HIV could result in medication-free remission for many – study

An unexpectedly high percentage of children born with HIV and started treatment within 48 hours of life exhibit biomarkers by two years of age that may make them eligible to test for medication-free remission.

An unexpectedly high percentage of children born with HIV and started treatment within 48 hours of life exhibit biomarkers by two years of age that may make them eligible to test for medication-free remission, according to a multinational study published in Lancet HIV.

Photo by zelle duda from Unsplash.com

“Moving away from reliance on daily antiretroviral therapy (ART) to control HIV would be a huge improvement to the quality of life of these children,” said Protocol Co-Chair and senior author Ellen Chadwick, MD, former Director of Section of Pediatric, Adolescent and Maternal HIV Infection at Ann & Robert H. Lurie Children’s Hospital of Chicago and Professor of Pediatrics at Northwestern University Feinberg School of Medicine.

The proof-of-concept study was charged with replicating the case of HIV remission as seen in the “Mississippi baby” that was reported in 2013. In that case, the infant started ART at 30 hours of life, was treated for 18 months, and achieved 27 months of ART-free remission before the virus rebounded. Typically, if ART is stopped, the virus rebounds within a month.

The study included a three-drug ART regimen initiated within 48 hours of life, with the fourth drug added within 2-4 weeks. This is very early treatment compared to the standard of care where three-drug ART may not begin until 2- 3 months of age. In the U.S., however, based on earlier findings from this study, very early treatment is now the norm for infants at high risk of acquiring HIV infection from their mother.

“With earlier treatment, we hope to limit or prevent the establishment of viral reservoirs in the body. These viral reservoirs hold small amounts of hidden virus which are hard to reach with ART. By shrinking these reservoirs, we expect to increase the amount of time that patients can be in remission, without needing daily ART,” said co-author Jennifer Jao, MD, MPH, from Lurie Children’s, who is the Protocol Co-Chair with Dr. Chadwick. She is a Professor of Pediatrics at Northwestern University Feinberg School of Medicine and holds the Susan B. DePree Founders’ Board Professorship in Pediatric, Adolescent, and Maternal HIV Infection.

“Our results show a higher percentage of children might be eligible to interrupt therapy than we expected, and the next step is to stop ART and see how many children actually achieve remission,” said Dr. Chadwick. “If even one child achieves remission, that would be considered a success. Today, newer more effective and better tolerated HIV medications are available for infants than when the study began, strengthening the prospect of limiting viral reservoirs and testing for possible remission in infants and children with HIV. Overall, this is an exciting advancement and an opportunity to change the course of pediatric HIV infection.”

The study was conducted in 11 countries – Brazil, Haiti, Kenya, Malawi, South Africa, Tanzania, Thailand, Uganda, USA, Zambia and Zimbabwe.

Advertisement. Scroll to continue reading.
Advertisement
Advertisement

Like Us On Facebook

YOU MAY ALSO LIKE

POZ

The amount allocated for every Filipino living with HIV under the Outpatient HIV/AIDS Treatment (OHAT) Package of the Philippine Health Insurance Corporation (PhilHealth) has...

POZ

Women with HIV experience accelerated DNA aging, a phenomenon that can lead to poor physical function.

From the Editor

May mga yumayaman sa HIV “advocacy”. And this is maddening because this often comes at the expense of PLHIVs themselves. So we say, enough....

From the Editor

Yes, seminars are essential in LGBTQIA and HIV advocacy. But for some, it's the be-all/end-all of all efforts, giving rise to 'seminar activists' who...

Advertisement